Hereditary Neuropathy Foundation

Hereditary Neuropathy Foundation is dedicated to making a significant impact in the realm of inherited neuropathies. As a non-profit 501(c)3 organization, Hereditary Neuropathy Foundation is committed to increasing awareness and ensuring accurate diagnosis of Charcot-Marie-Tooth (CMT) and related conditions. The foundation passionately supports patients and their families, providing crucial information to enhance their quality of life, while also funding vital research aimed at discovering effective treatments and cures.

Hereditary Neuropathy Foundation spearheads the Therapeutic Research in Accelerated Discovery (TRIAD), established in 2007. This collaborative initiative unites academia, government, and industry to accelerate the development of treatments for CMT. TRIAD currently engages numerous groups across the drug discovery, drug development, and diagnostics spectrum. With Hereditary Neuropathy Foundation's support, clinical trials are underway to treat the most common type of CMT, CMT1A, alongside other drugs and gene therapies in development for various types of CMT. The primary address for Hereditary Neuropathy Foundation is 401 Park Ave S, New York, 10016, US.

Hereditary Neuropathy Foundation continues to be a driving force in the fight against inherited neuropathies, fostering hope and progress for individuals and families affected by these conditions. The team at Hereditary Neuropathy Foundation is working diligently to provide complete information and updates, which will be available soon. We invite the manager of Hereditary Neuropathy Foundation to create a customized and exclusive company showcase and product listing on our platform to further highlight your impactful work.